144870-96-2

Basic information

• Product Name: 3-Furanol,4-aminotetrahydro-(9CI)
• Synonyms: 3-Furanol,4-aminotetrahydro-(9CI);4-aminotetrahydro-3-Furanol;4-aMinooxolan-3-ol;3-Furanol, 4-aMinotetrahydro-
• CAS NO: 144870-96-2
• Molecular Formula: C₄H₉NO₂
• Molecular Weight: 103.11976
• Product Categories: VARIOUSAMINE
• Mol File: 144870-96-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 3-Furanol,4-aminotetrahydro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Furanol,4-aminotetrahydro-(9CI)(144870-96-2)
• EPA Substance Registry System: 3-Furanol,4-aminotetrahydro-(9CI)(144870-96-2)

Safety Data

• Hazardous Substances Data: 144870-96-2(Hazardous Substances Data)

Usage

Uses

Due to the limited information available on 3-Furanol,4-aminotetrahydro-(9CI), its specific applications and uses cannot be accurately listed. However, given its classification as a furane derivative and the presence of an amino group and a tetrahydro structural piece, it is possible that 3-Furanol,4-aminotetrahydro-(9CI) may have potential applications in various industries, such as pharmaceuticals, chemical synthesis, or materials science. Further research and documentation are required to determine its exact uses and benefits.

Upstream product

• 285-69-8 3,4-epoxytetrahydrofuran 

Downstream Products

• 1430230-65-1 tert-butyl 4-hydroxytetrahydrofuran-3-ylcarbamate 
• 1279095-99-6 C₁₂H₁₉NO₃ 
• 1430230-65-1 (±)-trans-3-tert-butoxycarbonylamino-4-hydroxytetrahydrofuran 
• 215940-61-7 [(S)-1-(4-Hydroxy-tetrahydro-furan-3-ylcarbamoyl)-3-methyl-butyl]-carbamic acid benzyl ester 

Relevant articles and documents

Bronsted acid-catalyzed desymmetrization of meso-aziridines

The enantioselective ring-opening of meso-aziridines with azide nucleophiles proceeded in the presence of a catalytic amount of a chiral phosphoric acid catalyst. The reaction affords the formation of the products in excellent yield and enantioselectivity. Preliminary mechanistic studies indicate that the active catalytic species is a chiral silane that is generated in situ. Copyright

SALT FORM AND CRYSTAL FORM OF COMPOUND AS FGFR4 INHIBITOR AND PREPARATION METHOD THEREOF

The present invention provides a salt form, a crystal form, and a preparation method of a compound as an FGFR4 inhibitor and medical uses thereof.

HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS

Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE

Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

SELECTIVE ANDROGEN RECEPTOR MODULATORS

The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof.

Kinase inhibitor compounds

The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of kinase-mediated processes, and treatment of disease and disease symptoms, particularly those mediated by certain kinase enzymes.

KINASE INHIBITOR COMPOUNDS

The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of kinase-mediated processes, and treatment of disease and disease symptoms, particularly those mediated by certain kinase enzymes.

Structure-activity studies of cyclic ketone inhibitors of the serine protease plasmin: Design, synthesis, and biological activity

Three series of cyclic ketone inhibitors were synthesized and evaluated against the serine protease plasmin. Peptide inhibitors that incorporated 3-oxotetrahydrofuran and 3-oxotetrahydrothiophene 1,1-dioxide groups had the highest activities. Alkylamino substituents, which were designed to bind in the S1 subsite of plasmin, were attached to the inhibitors. Compounds 5c and 5g, which incorporated 6-aminohexyl substituents, were found to be optimal and demonstrated IC50 values in the low micromolar range. Incorporating conformationally constrained peptide segments into the inhibitors did not improve their activities.

Organolithium-induced alkylative ring opening of aziridines: Synthesis of unsaturated amino alcohols and ethers

Organolithium-induced alkylative ring opening of N-sulfonyl-protected aziridinyl ethers is described. The reactions were efficiently carried out with a variety of organolithiums, providing a promising new strategy to unsaturated amino alcohols and ethers.

Method and compositions for identifying anti-HIV therapeutic compounds

Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.